CORB.F Stock Overview
Provides umbilical cord blood storage and ancillary services in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Global Cord Blood Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.50 |
| 52 Week High | US$2.33 |
| 52 Week Low | US$0.85 |
| Beta | 0 |
| 1 Month Change | 20.00% |
| 3 Month Change | 0% |
| 1 Year Change | 23.97% |
| 3 Year Change | -64.87% |
| 5 Year Change | -68.42% |
| Change since IPO | -74.92% |
Recent News & Updates
Recent updates
Global Cord Blood GAAP EPS of $0.14, revenue of $46.88M
Jul 05Pounce On Global Cord For The Year Of The Tiger
Apr 29Global Cord Blood Corp. Looks Anemic On Slow Growth, Regulatory Concerns
Apr 08Global Cord Blood: With 6.0x P/E And 24% EPS CAGR, Subscriber Growth Continues
Dec 01Global Cord Blood Is An Undervalued Business With Accelerating Growth, Benefiting From China's Policy Changes
Jul 30Global Cord Blood: New China Policy Catalyst, 146% Net Cash And 24% EPS CAGR
Jul 01Global Cord Blood announces NHC policy update
Jan 05Global Cord Blood reports FQ2 results
Nov 24Shareholder Returns
| CORB.F | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 19.0% | -4.1% | -2.4% |
| 1Y | 24.0% | -10.2% | 23.3% |
Return vs Industry: CORB.F exceeded the US Healthcare industry which returned -11.4% over the past year.
Return vs Market: CORB.F exceeded the US Market which returned 22.1% over the past year.
Price Volatility
| CORB.F volatility | |
|---|---|
| CORB.F Average Weekly Movement | 19.5% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CORB.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CORB.F's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Tina Zheng | www.globalcordbloodcorp.com |
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province.
Global Cord Blood Corporation Fundamentals Summary
| CORB.F fundamental statistics | |
|---|---|
| Market cap | US$140.61m |
| Earnings (TTM) | US$68.68m |
| Revenue (TTM) | US$170.40m |
0.0x
P/E Ratio0.0x
P/S RatioIs CORB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CORB.F income statement (TTM) | |
|---|---|
| Revenue | CN¥1.24b |
| Cost of Revenue | CN¥183.31m |
| Gross Profit | CN¥1.06b |
| Other Expenses | CN¥558.88m |
| Earnings | CN¥501.07m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CORB.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 09:43 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Global Cord Blood Corporation is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| Ye Yin | Brean Capital |
| Brian Tanquilut | Jefferies LLC |